The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.
 
Maria Isabel Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Andrew Schroeder
No Relationships to Disclose
 
Semanti Mukherjee
Stock and Other Ownership Interests - Regeneron
 
Yelena Kemel
No Relationships to Disclose
 
Ritesh R Kotecha
Consulting or Advisory Role - Eisai; Eisai
Research Funding - Allogene Therapeutics (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Chung-Han Lee
Honoraria - American Institute of Continuing Medical Education; Ideology Health; Intellisphere; Medscape; Research to Practice
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Cardinal Health; Eisai; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)
 
Neil J. Shah
Honoraria - MedNet, LLC; MedNet, LLC; MJH Life Sciences
Consulting or Advisory Role - Exelixis; Graticule; Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis
Travel, Accommodations, Expenses - Merck
 
Darren R. Feldman
Consulting or Advisory Role - BioNTech; Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Telix Pharmaceuticals
Other Relationship - UpToDate
 
Ying L Liu
Research Funding - AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Michael Francis Walsh
No Relationships to Disclose
 
Alicia Latham
No Relationships to Disclose
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; AstraZeneca; BMS; Genentech/Roche
 
Ying-Bei Chen
Consulting or Advisory Role - Inspirna
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Optos (I); Outlook Therapeutics (I); Regeneron (I); Regenxbio (I)
 
Diana Mandelker
No Relationships to Disclose
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Aveo; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Merck; Pfizer
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb